Anti-payload antibody in PK study in ADC drug development
Anti-payload antibodies for ADCs aim to enhance safety and efficacy by neutralizing free cytotoxic
drugs, reducing off-target effects. They facilitate precise drug delivery, improve therapeutic
profiles, and enable drug monitoring, marking a significant advancement in targeted cancer therapy
with potential for personalized treatment strategies.
| Cat No. | Payload | Product Name | Fc | Technical Information | Products Information |
| GTU-Bios-Maytansinoids-Ab | DM1/DM4 | Anti-DM1/DM4 monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Auristatin-Ab-01 | MMAE/MMAF | Anti-MMAE/MMAF monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Auristatin-Ab-02 | MMAE (Specific) | Anti-MMAE (Specific) monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-DXd-Ab | DXd/Exatecan | Anti-DXd&Exatecan monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-CPT-Ab | Camptothecin (CPT) | Anti-CPTmonoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Eribulin-Ab | Eribulin | Anti-Eribulin monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Exatecan-Ab | Exatecan | Anti-Exatecan monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-SN-38-Ab | SN-38 | Anti-SN-38 monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Budesonide-Ab | Budesonide | Anti-Budesonide monoclonal antibody (mAb) | hFc/mFc | More | Details |
| GTU-Bios-MTX-Ab | MTX | Anti-MTX monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-PBD-Ab | PBD | Anti-PBD monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-PNU-159682-Ab | PNU-159682 | Anti-PNU-159682 monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Amanitin-Ab | Amanitin | Anti-Amanitin monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Calicheamicin-Ab | Calicheamicin | Anti-Calicheamicin monoclonal antibody(mAb) | hFc/mFc | More | Details |
| GTU-Bios-Doxorubicin-Ab | Doxorubicin | Anti-Doxorubicin monoclonal antibody (mAb) | hFc/mFc | More | Details |
| GTU-Bios-Duocarmycin-Ab | Duocarmycin | Anti-Duocarmycin monoclonal antibody (mAb) | hFc/mFc | More | Details |
GeneMedi's Case study of Anti-payload antibody
- Figure 1: Coating PTM-1 MMAE
- Figure 2: Coating PTM-1 MMAF
- Figure 3: Coating PTM-1 DXD
Figure 1. GMP-Bios-MMAE-Ab-2 and GMP-Bios-MMAE-Ab-3 have been actively bound with the ADC (PTM-1 MMAE).
Figure 1 demonstrates the efficacy of
GeneMedi's GMP-Bios-MMAE-Ab-2
and GMP-Bios-MMAE-Ab-3 in
actively binding with the ADC (PTM-1 MMAE). This underscores GeneMedi's
commitment to
producing
high-quality antibodies tailored for effective conjugation with MMAE-based ADCs.
The robust
binding
displayed in the figure highlights GeneMedi's expertise in developing antibodies
optimized
for
targeted drug delivery, a critical aspect in the field of antibody-drug
conjugates.
Figure 2. The GMP-Bios-MMAE-Ab-2 has been actively bound with the ADC (PTM-1 MMAF). While GMP-Bios-MMAE-Ab-3 has not been bound with the ADC with MMAF.
In Figure 2, the specificity of
GeneMedi's antibodies is showcased
as GMP-Bios-MMAE-Ab-2 successfully
binds with the ADC (PTM-1 MMAF), while GMP-Bios-MMAE-Ab-3 remains unbound. This
specificity
is
pivotal in ensuring precise targeting of MMAE-containing ADCs, enhancing their
therapeutic
efficacy
while minimizing off-target effects.
GeneMedi's ability to tailor antibodies to selectively
bind
with distinct drug payloads exemplifies their proficiency in antibody
engineering, offering
researchers reliable tools for precision medicine applications.
Figure 3. GMP-Bios-MMAE-Ab-2 and GMP-Bios-MMAE-Ab-3 have not been bound with the ADC conjugated with DXD.
Figure 3 illustrates another aspect
of GeneMedi's antibody
specificity, revealing that neither
GMP-Bios-MMAE-Ab-2 nor GMP-Bios-MMAE-Ab-3 binds with the ADC conjugated with
DXD. This data
underscores GeneMedi's dedication to producing antibodies with high selectivity,
ensuring
minimal
interference with undesired payloads.
By providing antibodies that exhibit minimal
cross-reactivity,
GeneMedi empowers researchers with precise tools for designing and optimizing
ADCs for
targeted
cancer therapy, ultimately advancing the forefront of biomedical research and
clinical
applications.
The Strategic Use of Anti-payload antibody in ADCs
The concept of an "anti-payload antibody" for Antibody-Drug Conjugates (ADCs) involves a unique strategy in the development and optimization of ADC therapies. Typically, ADCs consist of an antibody linked to a cytotoxic drug (payload) via a chemical linker. The antibody part of an ADC targets specific antigens on cancer cells, delivering the cytotoxic payload directly to these cells to kill them while sparing normal cells.
An "anti-payload antibody," on the other hand, is designed to recognize and bind to the payload molecule. This could serve multiple purposes:
-
Safety and Toxicity Management: By binding to free payload molecules that may have been released non-specifically in the body, these antibodies can potentially reduce off-target toxicity, improving the safety profile of ADC therapies.
-
Enhanced Precision: They could be used in research to better understand the biodistribution and clearance of the payload, leading to the design of more efficient and targeted ADCs.
-
Drug Monitoring: Anti-payload antibodies can be instrumental in developing assays to monitor the levels of the drug in the patient's system, allowing for personalized dose adjustments.
While the idea is still emerging in the field, the development of anti-payload antibodies represents an innovative approach to refine ADC technology further, aiming to maximize therapeutic efficacy while minimizing side effects in cancer treatment
Facebook
LinkedIn
Twitter
